for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Audentes Therapeutics Inc

BOLD.OQ

Latest Trade

26.85USD

Change

-0.33(-1.21%)

Volume

60,630

Today's Range

26.73

 - 

27.74

52 Week Range

18.00

 - 

41.59

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
27.18
Open
27.30
Volume
60,630
3M AVG Volume
9.08
Today's High
27.74
Today's Low
26.73
52 Week High
41.59
52 Week Low
18.00
Shares Out (MIL)
45.44
Market Cap (MIL)
1,235.12
Forward P/E
-6.24
Dividend (Yield %)
--

Latest Developments

More

Audentes Therapeutics Presents New Positive Data From Aspiro

Audentes Therapeutics Posts Q2 Loss Per Share Of $1.01

Audentes Therapeutics Presents New Positive Data From Aspiro

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Audentes Therapeutics Inc

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Industry

Biotechnology & Drugs

Contact Info

600 California St Fl 17

+1.415.6386556

https://www.audentestx.com/

Executive Leadership

Matthew R. Patterson

Chairman of the Board, Chief Executive Officer

Natalie C. Holles

President, Chief Operating Officer

Thomas J. Schuetz

Co-Founder, Independent Director

Thomas P. Soloway

Chief Financial Officer, Executive Vice President

Mark A. Meltz

Senior Vice President, General Counsel

Key Stats

2.33 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-5.590

2017

-3.400

2018

-3.400

2019(E)

-4.301
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.94
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-41.51
Return on Equity (TTM)
-39.34

Latest News

Latest News

BRIEF-Audentes Announces Data From First Dose Cohort Of ASPIRO

* AUDENTES ANNOUNCES CONTINUING POSITIVE DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY

BRIEF-Audentes Therapeutics Reports Qtrly Loss Per Share $0.74

* AUDENTES THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Audentes Therapeutics CEO Matthew Patterson's 2017 Total Compensation Was $6.9 Million

* AUDENTES THERAPEUTICS INC SAYS CEO MATTHEW PATTERSON'S 2017 TOTAL COMPENSATION WAS $6.9 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2KknZ9F) Further company coverage:

BRIEF-Audentes Therapeutics Q4 Loss Per Share ‍$0.82

* AUDENTES THERAPEUTICS REPORTS FOURTH QUARTER 2017 AND FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Wellington Management Group Llp Reports 10.85 pct Passive Stake In Audentes Therapeutics As Of Jan 31, 2018

* WELLINGTON MANAGEMENT GROUP LLP REPORTS 10.85 PERCENT PASSIVE STAKE IN AUDENTES THERAPEUTICS INC AS OF JANUARY 31, 2018 - SEC FILING Source text - (http://bit.ly/2nZykxi) Further company coverage:

BRIEF-Audentes Therapeutics Says Public Offering Of 5.75 Mln Shares Priced At $35/Share

* AUDENTES THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Audentes Therapeutics To Offer $150 Million Of Common Stock In Public Offering​

* AUDENTES THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Audentes Announces Positive Interim Data From First Dose Cohort Of Aspiro

* AUDENTES ANNOUNCES POSITIVE INTERIM DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY

BRIEF-Audentes Therapeutics Q3 ‍loss per share $ 0.88​

* Audentes Therapeutics reports third quarter 2017 financial results and provides corporate update

BRIEF-Audentes Therapeutics to release Q3 financial results Nov. 14

* Audentes Therapeutics to release third quarter 2017 financial results and provide corporate update on Tuesday, November 14, 2017 Source text for Eikon: Further company coverage:

BRIEF-Audentes Therapeutics gets fast track designation for its muscle disorder drug

* Audentes Therapeutics announces rare pediatric disease and fast track designations for AT132 for the treatment of x-linked myotubular myopathy

BRIEF-Audentes Therapeutics commences dosing of first patient in phase 1/2 trial of AT132 for the treatment of x-linked myotubular myopathy

* Audentes Therapeutics announces dosing of first patient in ASPIRO, a phase 1/2 clinical trial of AT132 for the treatment of X-linked myotubular myopathy

BRIEF-Audentes Therapeutics files for mixed shelf offering of up to $250 mln

* Audentes Therapeutics Inc files for mixed shelf offering of up to $250 million - sec filing Source text: (http://bit.ly/2fqe6ME) Further company coverage:

BRIEF-Audentes Therapeutics appoints Fulvio Mavilio to vice president scientific affairs, Europe

* Audentes Therapeutics announces appointment of Fulvio Mavilio, Ph.D. To vice president scientific affairs, Europe Source text for Eikon: Further company coverage:

BRIEF-Audentes Therapeutics qtrly loss per share $0.83

* Audentes therapeutics reports first quarter 2017 financial results and provides corporate update

BRIEF-Audentes Therapeutics files for common stock offering of about 4.8 mln shares

* Files for common stock offering of about 4.8 million shares - sec filing Source text: (http://bit.ly/2puDjWw) Further company coverage:

BRIEF-Audentes Therapeutics announces proposed public offering of common stock

* Audentes Therapeutics announces proposed public offering of common stock

BRIEF-Audentes Therapeutics announces FDA clearance of investigational new drug application for AT132 to treat x-linked myotubular myopathy

* Audentes Therapeutics announces FDA clearance of investigational new drug application for AT132 to treat x-linked myotubular myopathy

BRIEF-Audentes Therapeutics Q4 loss per share $ 0.91

* Audentes Therapeutics reports fourth quarter and full year 2016 financial results and provides corporate update

BRIEF-Audentes Therapeutics announces FDA clearance of investigational new drug application for AT342

* Audentes Therapeutics announces FDA clearance of investigational new drug application for AT342 to treat Crigler-Najjar Syndrome

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up